Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$72.00K$72.00K−94.0% vs Q3 2022 Net Income-$47.66M-$47.66MN/M vs Q3 2022 EPS Diluted-$1.09-$1.09N/M vs Q3 2022 Operating Income-$51,224,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$39,387,000N/M Margins · derivedOperating margin-71144.4%−68652.0 pt vs Q3 2022
Net margin-66194.4%−63775.6 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end